mRNA |
parbendazole |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-06 |
mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
1e-06 |
mRNA |
NVP-231 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-06 |
mRNA |
FQI-2 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-06 |
mRNA |
NSC-207895 |
GDSC1000 |
pan-cancer |
AAC |
0.16 |
1e-06 |
mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-06 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-06 |
mRNA |
PF-184 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-06 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
2e-06 |
mRNA |
paclitaxel |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-06 |